Co-Pay Assistance Program

Co-Pay Assistance Program

How to use the Zypitamag (pitavastatin) tablets Savings Card

  • Please print the Zypitamag Savings Card.
  • Present the Zypitamag Savings Card with your prescription to your pharmacy, and you may pay less on your prescriptions of Zypitamag.
  • If you are already taking Zypitamag, simply take your Zypitamag Savings Card to your pharmacy to begin receiving savings on your next refills.
  • On each 30-day supply of Zypitamag, your Zypitamag Savings Card will deduct from your out-of-pocket costs that exceed $10.00 (up to a maximum of $85.00).
  • For patients who receive a 90-day supply, the Zypitamag Savings Card will cover up to a maximum of $255.00 off.

To Patient: Take your Zypitamag (pitavastatin) tablets Savings Card along with your prescription to your pharmacist. This card covers out of pocket costs that exceed $10 (up to a maximum of $85 off) on each 30 day supply. For a 90 day supply, the card will cover up to a maximum of $255 off. You will be responsible for any remaining balance after the maximum benefits are applied with each use. For cash paying patients, this card covers up to $183 off for a 30 day supply.

To Pharmacist: For Insured Patients: Process a Coordination of Benefits (COB/split bill) claim using the patient's prescription insurance for the PRIMARY claim. Submit a SECONDARY claim to PDM under BIN: 610020.
For Insured Not Covered/Cash Patients: Submit a PRIMARY claim to PDM under BIN: 610020

For pharmacy processing questions, please call 1-888-831-7448
(Monday - Friday 24 hours, Saturday 8 AM - 7 PM EST, and Sunday 9 AM - 5 PM EST)

Eligibility Criteria: This offer is good for eligible patients purchasing Zypitamag and may not be used for any other product. This offer is good for the purchase of Zypitamag manufactured for Medicure and lawfully purchased from an authorized retailer or distributor in the United States or its territories. This offer is not insurance and is not valid for mail order or prescriptions purchased under Medicaid, Medicare, TriCare or similar federal or state programs or for patients who are Medicare eligible and enrolled in an employer-sponsored group waiver health plan or government-subsidized prescription drug benefit program for retirees. Offer not valid where prohibited by law, taxed or restricted. Patients enrolled in the Zypitamag Patient Assistance Program are not eligible to receive this offer. This offer is not transferable, is limited to one per person and may not be combined with any other offer. Offer must be presented along with a valid prescription for Zypitamag at the time of purchase. If you lose your card before the first time you use it, simply print or download a new copy at www.zypitamag.com and bring it to the pharmacy. Medicure reserves the right to change or discontinue this offer at any time without notice.

IMPORTANT SAFETY INFORMATION FOR ZYPITAMAG™ (pitavastatin)

INDICATIONS & USAGE

Drug therapy should be one component of multiple-risk-factor intervention in individuals who require modifications of their lipid profile. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol only when the response to diet and other nonpharmacological measures has been inadequate.

Primary Hyperlipidemia and Mixed Dyslipidemia: Zypitamag is indicated as an adjunctive therapy to diet to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hyperlipidemia or mixed dyslipidemia.

Limitations of Use: Doses of Zypitamag greater than 4 mg once daily were associated with an increased risk for severe myopathy in premarketing clinical studies. Do not exceed 4 mg once daily dosing of Zypitamag. The effect of Zypitamag on cardiovascular morbidity and mortality has not been determined. Zypitamag has not been studied in Fredrickson Type I, III, and V dyslipidemias.

CONTRAINDICATIONS

Zypitamag is contraindicated in patients with a known hypersensitivity to product components, in patients with active liver disease (which may include unexplained persistent elevations in hepatic transaminase levels), in women who are pregnant or may become pregnant, in nursing mothers or in coadministration with cyclosporine.

WARNINGS & PRECAUTIONS

Skeletal Muscle Effects: Cases of myopathy and rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with HMG-CoA reductase inhibitors, including pitavastatin.

  • These risks can occur at any dose level, but increase in a dose-dependent manner, with advanced age (≥ 65 years), renal impairment, and inadequately treated hypothyroidism; administer with caution in these patients, or when used concomitantly with fibrates or lipid-modifying doses of niacin, or colchicine. Avoid concomitant administration with gemfibrozil.
  • Advise patients to promptly report unexplained and/or persistent muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever; discontinue Zypitamag.
  • If muscle signs and symptoms persist after discontinuation, this may be a sign of immune-mediated necrotizing myopathy (IMNM), an autoimmune myopathy associated with statin use, requiring immediate medical attention. IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment; muscle biopsy showing necrotizing myopathy without significant inflammation; improvement with immunosuppressive agents.
  • Zypitamag should be discontinued if markedly elevated creatine kinase levels occur or myopathy is diagnosed or suspected.
  • Zypitamag should also be temporarily withheld in any patient with an acute, serious condition suggestive of myopathy or predisposing to the development of renal failure secondary to rhabdomyolysis (e.g., sepsis, hypotension, dehydration, major surgery, trauma, severe metabolic, endocrine, and electrolyte disorders, or uncontrolled seizures).

Liver Enzyme Abnormalities:

  • Persistent elevation in hepatic transaminases can occur. Check liver enzymes before initiating therapy and if signs or symptoms of liver injury occur; advise patients to report fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice.
  • Fatal and non-fatal hepatic failure can occur. Interrupt Zypitamag if serious liver injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs. If an alternate etiology is not found do not restart Zypitamag.
  • Use Zypitamag with caution in patients who consume substantial quantities of alcohol and/or have a history of chronic liver disease. Do not use Zypitamag if patient has active liver disease, which may include unexplained persistent transaminase elevations.

Endocrine Function:

  • Increases in HbA1c and fasting serum glucose levels have been reported.

COMMON ADVERSE REACTIONS

Myalgia, back pain, diarrhea, constipation and pain in extremity (rate ≥ 2% in at least one marketed dose). This is not a complete list of all reported adverse events.

For additional information, refer to full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.FDA.gov/medwatch
or call 1-800-FDA-1088